Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S M KornblauM Andreeff

Abstract

Expression of the multidrug resistance gene (MDR1) p170 protein is frequent in leukemic blasts from patients with relapsed acute myelogenous leukemia (AML). A phase I study using the nonimmunosuppressive MDR1 blocker SDZ PSC-833 (PSC) in combination with mitoxantrone (MITO) and etoposide (VP) was performed. Starting doses (LVL0) of MITO (3.25 mg/m2/d on days 1 and 3 to 6) and VP (210 mg/m2/d on days 1 and 3 to 5) were 40% of the maximal-tolerated dose (MTD) from a prior study. A 1.5-mg/kg loading dose of PSC was followed by a 120-hour continuous infusion of 10 mg/kg/d on days 2 to 6. Blood samples for PSC, MITO, and VP pharmacokinetics (PK) were taken on days 1 and 3, and samples for MDR1 expression were taken on day 0. Severe mucositis developed in all patients at LVL0; therefore, MITO and VP doses were reduced to 2.5 and 170 mg/m2 (LVL-1) for the next seven patients, and this dose proved to be MTD. All LVL0 and three LVL-1 patients had transient elevations in the serum bilirubin level to > or = 4 mg/dL. Serum creatinine level increased to greater than 2 mg/dL in one case. There were no other grade 3 or 4 nonhematologic toxicities observed. The peripheral blood was cleared of leukemia in three LVL0 and four LVL-1 patients. The...Continue Reading

Citations

Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U TidefeltC Paul
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R DorrA F List
Jul 5, 2005·Expert Opinion on Investigational Drugs·F Loor
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A PatnaikA M Oza
Oct 25, 2003·Oncogene·Tito Fojo, Susan Bates
Feb 27, 2001·Japanese Journal of Cancer Research : Gann·H MinamiY Sasaki
Jan 1, 2012·Scientifica·Jose J G Marin
May 10, 2002·Leukemia & Lymphoma·Tadeusz Robak, Agata Wrzesień-Kuś
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I ChicoS Bates
Mar 21, 2002·Nature Reviews. Cancer·Michael M GottesmanSusan E Bates
Mar 11, 2011·Science Translational Medicine·Edward K ChowDean Ho
Jan 15, 1999·Pathology Oncology Research : POR·G SzakácsB Sarkadi
Jun 3, 1999·European Journal of Clinical Investigation·J Robert
Jul 5, 2005·Expert Opinion on Investigational Drugs·J Robert
Mar 11, 2011·Science Translational Medicine·Timothy J Merkel, Joseph M DeSimone
Aug 22, 2000·Antimicrobial Agents and Chemotherapy·O MarchettiD Sanglard
Jul 9, 2009·Chemical Reviews·Paul D W Eckford, Frances J Sharom
May 18, 2001·Best Practice & Research. Clinical Haematology·P Sonneveld, A F List
Dec 4, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L A Garraway, B Chabner
Mar 14, 2012·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Brian C ShafferMichael M Gottesman

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.